Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2010-02-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm901386ePMID 20121196PMCID PMC2842983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening.

  2010cited by this paper
• Discovery of Wild-Type and Y181C Mutant Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors Using Virtual Screening with Multiple Protein Structures

  2009cited by this paper
• Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

  2009cited by this paper
• Efficient drug lead discovery and optimization.

  2009cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.

  2007cited by this paper
• From docking false-positive to active anti-HIV agent.

  2007cited by this paper
• Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.

  2007cited by this paper
• Prediction of protein-ligand interactions. Docking and scoring: successes and gaps.

  2006cited by this paper
• Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

  2006cited by this paper
• Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction.

  2006cited by this paper
• N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

  2006cited by this paper
• Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  2006cited by this paper
• ZINC - A Free Database of Commercially Available Compounds for Virtual Screening

  2005cited by this paper
• Molecular modeling of organic and biomolecular systems using BOSS and MCPRO

  2005cited by this paper
• Potential energy functions for atomic-level simulations of water and organic and biomolecular systems.

  2005cited by this paper
• Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

  2004cited by this paper
• Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

  2004cited by this paper
• Regulation of prostate growth by fibroblast growth factors

  2004cited by this paper
• Protein Kinase Inhibitors: Insights into Drug Design from Structure

  2004cited by this paper
• Virtual screening for kinase targets.

  2004cited by this paper
• Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.

  2004cited by this paper
• Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

  2003cited by this paper
• Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

  2003cited by this paper
• Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK).

  2003cited by this paper
• Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Structural basis of inhibitor selectivity in MAP kinases.

  1998cited by this paper
• Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.

  1998cited by this paper
• Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain

  1998cited by this paper
• Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

  1997cited by this paper
• Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

  1997cited by this paper
• Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.

  1997cited by this paper
• Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids

  1996cited by this paper
• Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.

  1996cited by this paper
• Expression of fibroblast growth factor‐1 (FGF‐1), FGF‐2 and FGF receptor‐1 in a human salivary‐gland adenocarcinoma cell line: Evidence of autocrine growth

  1996cited by this paper
• Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II

  1996cited by this paper
• [Regulators of angiogenesis].

  1996cited by this paper
• Expression of fibroblast growth factor-1 (FGF-1), FGF-2 and FGF receptor-1 in a human salivary-gland adenocarcinoma cell line: evidence of growth.

  1996cited by this paper
• Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.

  1996cited by this paper
• Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

  1996cited by this paper
• Constitutive Activation of Fibroblast Growth Factor Receptor-2 by a Point Mutation Associated with Crouzon Syndrome (*)

  1995cited by this paper
• Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3

  1995cited by this paper
• Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast

  1995cited by this paper
• Expression of fgf and fgf receptor genes in human breast cancer

  1995cited by this paper
• MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands.

  1994cited by this paper
• Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer

  1994cited by this paper
• Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

  1994cited by this paper
• Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia

  1994cited by this paper
• Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

  1994cited by this paper
• Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas

  1994cited by this paper
• Expression of the FGFR1 gene in human breast‐carcinoma cells

  1994cited by this paper
• Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome

  1994cited by this paper
• [Growth factors and cancer].

  1994cited by this paper
• Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer

  1993cited by this paper
• Amplification of fgfr4 gene in human breast and gynecological cancers

  1993cited by this paper
• FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers

  1993cited by this paper
• Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome—associated Kaposi sarcoma tissue and derived cells

  1993cited by this paper
• Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction.

  1992cited by this paper
• The FGF family of growth factors and oncogenes.

  1992cited by this paper
• Molecular Genetics of Cancer

  1992cited by this paper
• Growth factors and cancer.

  1991cited by this paper
• BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.

  1991cited by this paper
• Regulators of angiogenesis.

  1991cited by this paper
• Oncogenes and tumor-suppressor genes.

  1991cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Biological and biochemical properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis.

  1989cited by this paper
• The molecular genetics of cancer.

  1987cited by this paper

• One-Pot Gateway to Quinazoline-Thiohydantoin Fused Scaffolds and Discovery of Their Antileukemic Activity.

  2026cites this paper
• Laser-Induced Dimeric Photoproducts of Chlorpromazine: LC-MS Identification and Molecular Docking Evidence of Enhanced Anticancer Potential

  2025cites this paper
• Alkoxyalkylation of Electron-Rich Aromatic Compounds

  2024cites this paper
• The role of GZMA as a target of cysteine and biomarker in Alzheimer’s disease, pelvic organ prolapse, and tumor progression

  2024cites this paper
• Actives-Based Receptor Selection Strongly Increases the Success Rate in Structure-Based Drug Design and Leads to Identification of 22 Potent Cancer Inhibitors

  2022cites this paper
• Absolute binding free energy calculations improve enrichment of actives in virtual compound screening

  2022cites this paper
• A Guide to In Silico Drug Design

  2022cites this paper
• Applications of machine learning in computer-aided drug discovery

  2022cites this paper
• Physics of biomolecular recognition and conformational dynamics

  2021cites this paper
• Structure–activity relationships and drug design

  2021cites this paper
• Decision Making in Structure-Based Drug Discovery: Visual Inspection of Docking Results.

  2021cites this paper
• Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study

  2020cites this paper
• Investigation on penetration of saffron components through lipid bilayer bound to spike protein of SARS-CoV-2 using steered molecular dynamics simulation

  2020cites this paper
• Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase

  2020cites this paper
• Rigorous Free Energy Simulations in Virtual Screening

  2020cites this paper
• Cosolvent-Based Protein Pharmacophore for Ligand Enrichment in Virtual Screening

  2019cites this paper
• Facile preparation of 3-substituted 2-quinazolinones via electrogenerated base

  2018cites this paper
• Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors.

  2018cites this paper
• New fluorescence‐based high‐throughput screening assay for small molecule inhibitors of tyrosyl‐DNA phosphodiesterase 2 (TDP2)

  2018cites this paper
• Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors.

  2017cites this paper
• Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1

  2016cites this paper
• Design , synthesis , and biological evaluation of 3-vinyl-quinoxalin-2 ( 1 h )-one derivatives as novel antitumor inhibitors of FgFr 1

  2016cites this paper
• Docking and Ligand Binding Affinity: Uses and Pitfalls

  2016cites this paper
• In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study

  2016cites this paper
• Synthesis and Evaluation of Biological and Antitumor Activities of Tetrahydrobenzothieno[2,3‐d]Pyrimidine Derivatives as Novel Inhibitors of FGFR1

  2016cites this paper
• Computer-aided discovery of new FGFR-1 inhibitors followed by in vitro validation.

  2016cites this paper
• Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis

  2015cites this paper
• Protein–Ligand Docking: Virtual Screening and Applications to Drug Discovery

  2015cites this paper
• Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1

  2015cites this paper
• Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3)

  2015cites this paper
• Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.

  2015cites this paper
• Protein tyrosine phosphatases: Ligand interaction analysis and optimisation of virtual screening.

  2014cites this paper
• Computational Methods in Drug Discovery

  2014cites this paper
• synthesis and biological evaluation of novel indole-2one and 7-aza-2-oxindole derivatives as anti-inflammatory agents

  2014cites this paper
• Identification and Validation of Novel PERK Inhibitors

  2014cites this paper
• Distinguishing Binders from False Positives by Free Energy Calculations: Fragment Screening Against the Flap Site of HIV Protease

  2014cites this paper
• Design, synthesis, physicochemical, and pharmacological evaluation of gallic acid esters as non-ulcerogenic and gastroprotective anti-inflammatory agents

  2014influential citation
• Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations.

  2014cites this paper
• Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential

  2014cites this paper
• Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors

  2013cites this paper
• Ligand Pose and Orientational Sampling in Molecular Docking

  2013cites this paper
• Rational drug design: the search for Ras protein hydrolysis intermediate conformation inhibitors with both affinity and specificity.

  2013cites this paper
• In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features

  2013cites this paper
• Targeting the fibroblast growth factor receptors for the treatment of cancer.

  2013cites this paper
• Synthesis, evaluation, and molecular docking studies of cycloalkyl/aryl-3,4,5-trimethylgallates as potent non-ulcerogenic and gastroprotective anti-inflammatory agents

  2013influential citation
• Fibroblast growth factor receptor inhibitors.

  2012cites this paper
• Steered Molecular Dynamics-A Promising Tool for Drug Design

  2012influential citation
• Pharmacological Evaluation of Some Novel Glitazones as Antidiabetic Agents.

  2012influential citation
• Application of a post-docking procedure based on MM-PBSA and MM-GBSA on single and multiple protein conformations.

  2012cites this paper
• A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.

  2012cites this paper
• Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.

  2012cites this paper
• Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review

  2012cites this paper
• Software and resources for computational medicinal chemistry.

  2011cites this paper
• The role of computational methods in the identification of bioactive compounds.

  2011cites this paper
• A Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases

  2011cites this paper
• Using Free Energy of Binding Calculations To Improve the Accuracy of Virtual Screening Predictions

  2011cites this paper
• Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity.

  2011cites this paper
• Pharmacophore modelling: a forty year old approach and its modern synergies.

  2011cites this paper
• Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.

  2011cites this paper
• Disubstituted 2-phenyl-benzopyranopyrimidine derivatives as a new type of highly selective ligands for telomeric G-quadruplex DNA.

  2011cites this paper
• Task‐parallel message passing interface implementation of Autodock4 for docking of very large databases of compounds using high‐performance super‐computers

  2011cites this paper
• Aryl Extensions of Thienopyrimidinones as Fibroblast Growth Factor Receptor 1 Kinase Inhibitors.

  2011cites this paper
• Structure-based design of potent aromatase inhibitors by high-throughput docking.

  2011cites this paper
• Synthesis of purin-2-yl and purin-6-yl-aminoglucitols as C-nucleosidic ATP mimics and biological evaluation as FGFR3 inhibitors.

  2011cites this paper
• Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening.

  2010cites this paper
• Docking compared to 3D-pharmacophores: the scoring function challenge

  2010cites this paper